Nilotinib-induced Vasculopathy: Identification of Vascular Endothelial Cells As a Primary Target Site

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Aug 1

PMID 28757617

Citations 68

Authors

E Hadzijusufovic

K Albrecht-Schgoer

K Huber

G Hoermann

F Grebien

G Eisenwort

W Schgoer

S Herndlhofer

C Kaun

M Theurl

W R Sperr

U Rix

I Sadovnik

B Jilma

G H Schernthaner

J Wojta

D Wolf

G Superti-Furga

R Kirchmair

P Valent

Affiliations

Soon will be listed here.

Abstract

The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease (AOD). Our objective was to determine the exact frequency of AOD and examine in vitro and in vivo effects of Nilotinib and Imatinib on endothelial cells to explain AOD-development. In contrast to Imatinib, Nilotinib was found to upregulate pro-atherogenic adhesion-proteins (ICAM-1, E-selectin, VCAM-1) on human endothelial cells. Nilotinib also suppressed endothelial cell proliferation, migration and tube-formation and bound to a distinct set of target-kinases, relevant to angiogenesis and atherosclerosis, including angiopoietin receptor-1 TEK, ABL-2, JAK1 and MAP-kinases. Nilotinib and siRNA against ABL-2 also suppressed KDR expression. In addition, Nilotinib augmented atherosclerosis in ApoE-/- mice and blocked reperfusion and angiogenesis in a hindlimb-ischemia model of arterial occlusion, whereas Imatinib showed no comparable effects. Clinically overt AOD-events were found to accumulate over time in Nilotinib-treated patients. After a median observation-time of 2.0 years, the AOD-frequency was higher in these patients (29.4%) compared to risk factor- and age-matched controls (<5%). Together, Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells, which may contribute to development of AOD in patients with CML.

Citing Articles

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases.

Sasaki N, Enomoto Y, Hori T, Matsubara H, Egashira Y, Izumo T BMC Neurol. 2025; 25(1):6.

PMID: 39754083 PMC: 11697887. DOI: 10.1186/s12883-024-04006-2.

Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis.

Sibal S, Patankar A, Raut T Cureus. 2024; 16(11):e72952.

PMID: 39634983 PMC: 11615558. DOI: 10.7759/cureus.72952.

Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.

Travers R, Stepanian A, Jaffe I Arterioscler Thromb Vasc Biol. 2024; 44(10):2143-2153.

PMID: 39145393 PMC: 11424247. DOI: 10.1161/ATVBAHA.124.319864.

Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.

Fernando F, Andres M, Claudiani S, Kermani N, Ceccarelli G, Innes A Cardiooncology. 2024; 10(1):42.

PMID: 39010172 PMC: 11247904. DOI: 10.1186/s40959-024-00245-x.

The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling.

Zibrova D, Ernst T, Hochhaus A, Heller R Mol Cell Biochem. 2024; 480(3):1627-1643.

PMID: 39009935 PMC: 11842422. DOI: 10.1007/s11010-024-05070-5.

References

Blankenberg S, Barbaux S, Tiret L . Adhesion molecules and atherosclerosis. Atherosclerosis. 2003; 170(2):191-203. DOI: 10.1016/s0021-9150(03)00097-2. View

Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G . Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009; 114(24):4933-8. DOI: 10.1182/blood-2009-07-232595. View

Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9. DOI: 10.1056/NEJMoa0912614. View

Bankl H, Grossschmidt K, Pikula B, Bankl H, Lechner K, Valent P . Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Hum Pathol. 1999; 30(2):188-94. DOI: 10.1016/s0046-8177(99)90274-5. View

Giles F, Mauro M, Hong F, Ortmann C, McNeill C, Woodman R . Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013; 27(6):1310-5. DOI: 10.1038/leu.2013.69. View

Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Ray A . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7(2):129-41. DOI: 10.1016/j.ccr.2005.01.007. View

Quintas-Cardama A, Cortes J . Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 2008; 4(5):611-21. DOI: 10.2217/14796694.4.5.611. View

El-Agamy D . Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits. Hum Exp Toxicol. 2016; 36(11):1131-1145. DOI: 10.1177/0960327116681649. View

Copland M, Jorgensen H, Holyoake T . Evolving molecular therapy for chronic myeloid leukaemia--are we on target?. Hematology. 2005; 10(5):349-59. DOI: 10.1080/10245330500234195. View

10.

Hulthe J, Wikstrand J, Mattsson-Hulten L, Fagerberg B . Circulating ICAM-1 (intercellular cell-adhesion molecule 1) is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58-year-old men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond). 2002; 103(2):123-9. DOI: 10.1042/cs1030123. View

11.

Katgi A, Sevindik O, Adan Gokbulut A, Ozsan G, Yuksel F, Solmaz S . Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion. Clin Appl Thromb Hemost. 2014; 21(7):678-83. DOI: 10.1177/1076029614550817. View

12.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M . New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica. 2005; 90(4):534-41. View

13.

Tefferi A, Letendre L . Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011; 86(7):610-1. DOI: 10.1002/ajh.22051. View

14.

Alhawiti N, Burbury K, Kwa F, OMalley C, Shuttleworth P, Alzard M . The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016; 145:54-64. DOI: 10.1016/j.thromres.2016.07.019. View

15.

Lassila M, Jandeleit-Dahm K, Seah K, Smith C, Calkin A, Allen T . Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol. 2004; 16(2):363-73. DOI: 10.1681/ASN.2004050392. View

16.

Cortes J, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C . A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369(19):1783-96. PMC: 3886799. DOI: 10.1056/NEJMoa1306494. View

17.

Sattler M, Griffin J . Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003; 40(2 Suppl 2):4-10. DOI: 10.1053/shem.2003.50034. View

18.

Chislock E, Pendergast A . Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One. 2013; 8(12):e85231. PMC: 3868616. DOI: 10.1371/journal.pone.0085231. View

19.

Fowkes F, Rudan D, Rudan I, Aboyans V, Denenberg J, McDermott M . Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901):1329-40. DOI: 10.1016/S0140-6736(13)61249-0. View

20.

Kim T, Rea D, Schwarz M, Grille P, Nicolini F, Rosti G . Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013; 27(6):1316-21. DOI: 10.1038/leu.2013.70. View